Mass Vaccine and Drug Administration, Bangladesh

Launched by UNIVERSITY OF OXFORD · Sep 28, 2023

Keywords

ClinConnect Summary

This clinical trial, called the Mass Vaccine and Drug Administration study in Bangladesh, is looking at ways to help prevent Plasmodium Falciparum malaria, a serious type of malaria. Researchers want to compare the effectiveness of several approaches: giving people medicine, providing vaccines, or using a combination of both, against the usual treatment currently available. The study is open to individuals aged 6 months and older who live in specific villages, as long as they can provide consent (or have a parent or guardian provide it if they are under 18).

If you participate in this trial, you will be part of a community effort to see if these new methods can better protect against malaria. However, some people may not be eligible, like those who are pregnant, breastfeeding, or currently sick, as well as those who have had bad reactions to similar treatments before. The study is currently recruiting participants, and it’s a great opportunity to contribute to research that could improve malaria prevention in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Current residence in a study village irrespective of permanence
• • Age 6 months and above (no upper age limit)
• • Written informed consent provided by participants (or a parent/guardian in case the participant is under 18 years old)
• Exclusion Criteria:
• • Pregnancy, plan to get pregnant, or breastfeeding.
• • Acute illness requiring intervention
• • A history of an adverse reaction to study drugs/vaccine and prior receipt of any other malaria vaccine or enrolment in another intervention trial.